ILMN vs. AVTR, PKI, A, MTD, WAT, TECH, CRL, BRKR, BIO, and PACB
Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Avantor (AVTR), Revvity (PKI), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Bio-Rad Laboratories (BIO), and Pacific Biosciences of California (PACB).
Illumina (NASDAQ:ILMN) and Avantor (NYSE:AVTR) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Illumina has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Avantor has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Illumina received 915 more outperform votes than Avantor when rated by MarketBeat users. Likewise, 65.78% of users gave Illumina an outperform vote while only 63.81% of users gave Avantor an outperform vote.
Avantor has a net margin of 3.79% compared to Illumina's net margin of -28.71%. Avantor's return on equity of 13.01% beat Illumina's return on equity.
In the previous week, Avantor had 6 more articles in the media than Illumina. MarketBeat recorded 23 mentions for Avantor and 17 mentions for Illumina. Illumina's average media sentiment score of 1.04 beat Avantor's score of 0.69 indicating that Illumina is being referred to more favorably in the media.
Illumina presently has a consensus price target of $158.57, suggesting a potential upside of 31.67%. Avantor has a consensus price target of $25.93, suggesting a potential upside of 1.32%. Given Illumina's higher possible upside, equities analysts clearly believe Illumina is more favorable than Avantor.
Avantor has higher revenue and earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
89.4% of Illumina shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 0.2% of Illumina shares are owned by insiders. Comparatively, 1.5% of Avantor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Avantor beats Illumina on 13 of the 18 factors compared between the two stocks.
Get Illumina News Delivered to You Automatically
Sign up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Illumina Competitors List
Related Companies and Tools
Free ILMN Stock Alerts